AI platform for analyzing heart CT scans to assess coronary artery disease
Studies an AI platform that analyzes heart CT scans for coronary artery disease in adults.
Plain-language title generated from the registry record
Registry title: AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry
Key facts
- Where
- Singapore, SingaporeSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 80 years old?
Source: NCT05509010, who can take part
Where in Singapore
- National Heart Centre SingaporeSingapore, SingaporeTaking people
- National University HospitalSingapore, SingaporeTaking people
- Tan Tock Seng HospitalSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Heart Centre Singapore
- Trial code
- NCT05509010
- Record updated
- 19 August 2022
- Original description
The overall aim is to build an AI driven national Platform for CT cOronary angiography for clinicaL and industriaL applicatiOns (APOLLO) for automated anonymization, reporting, Agatston scoring and plaque quantification in CAD. It is a "one-stop" platform spanning diagnosis to clinical management and prognosis, and aid in predicting pharmacotherapy response.Read full original descriptionShow less
AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)
The overall aim is to build an AI driven national Platform for CT cOronary angiography for clinicaL and industriaL applicatiOns (APOLLO) for automated anonymization, reporting, Agatston scoring and plaque quantification in CAD. It is a "one-stop" platform spanning diagnosis to clinical management and prognosis, and aid in predicting pharmacotherapy response.
Inclusion: Age ≥21 years old; Signed informed consent; Clinically indicated for evaluation by CTCA.
Exclusion: Concomitant participation in another clinical trial in which subject is subject to investigational drug or device; Cardiac event and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) and/or valvular repair/replacement prior to CTCA; Known complex congenital heart disease; Known allergy to iodinated contrast agent; Non-cardiac illness with life expectancy < 2 years; Individuals unable to provide informed consent; Planned invasive angiography for reasons other than CAD; Pregnancy; Glomerular Filtration Rate ≤ 30mL/min; Contraindications to beta blockers or nitroglycerin or adenosine.